

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

- 1-6. (Canceled)
7. (Currently amended) ~~Reagent according to one of the claim 1, characterized in that the reagent is available from a culture medium of~~ A reagent that binds CD30, wherein the reagent is (1) an antibody produced by the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548; (2) a humanized version of the antibody; or (3) a fragment of the antibody or the humanized antibody, wherein the humanized antibody and the fragment bind CD30 at the same epitope as the antibody produced by the cell DSZ1 stored at the DSM under the number DSM ACC2548.
8. (Withdrawn, currently amended) ~~Reagent according to one of the claim 1~~ The reagent of claim 7, characterized in that it also contains which is linked to a toxin and/or a marking.
9. (Currently amended) ~~Reagent according to~~ The reagent of Claim 8, characterized in that it is linked peptidically or via linker molecules with toxic proteins or with enzymes or proenzymes a linker molecule to a molecule selected from the group consisting of a toxic protein, an enzyme, and a proenzyme.
10. (Withdrawn, currently amended) ~~Reagent according to~~ The reagent of Claim 9, characterized in that it is linked with toxins in the form of ribosome inactivating proteins wherein the toxic protein is a ribosome-inactivating protein.

11. (Currently amended) ~~Reagent according to~~ The reagent of Claim 9, characterized in that it is linked with enzymes from the group of the phosphodiesterases wherein the enzyme is a phosphodiesterase.

12. (Withdrawn, currently amended) ~~Reagent according to~~ The reagent of Claim 9, characterized in that it is linked directly or via a linker molecule covalently or conjugated with radioactive isotopes a radioactive isotope.

13. (Withdrawn, currently amended) ~~Reagent according to~~ The reagent of Claim 12, characterized in that the radioactive isotopes are wherein the radioactive isotope is selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. (Withdrawn, currently amended) ~~Reagent according to~~ The reagent of claim 8, characterized in that it is linked directly or via linker molecules a linker molecule covalently or conjugated with photactivatable compounds a photoactivatable compound.

15-17. (Canceled)

18. (Currently amended) ~~Isolated~~ An isolated cell according to claim 15, characterized in that it was stored at the DSM under the no. DSM ACC2548.

19. (Withdrawn, currently amended) ~~Method~~ A method for the diagnosis especially of tumours diagnosing CD30-positive tumors and inflammatory diseases, characterized in that comprising the steps of: (a) contacting a sample from the a test person is contacted with a reagent according to claim 1 of claim 7; and (b) detecting the extent of the reaction binding of the reagent with the sample is determined, wherein the binding indicates the presence of a CD30-positive tumor or an inflammatory disease.

20. (Canceled)

21. (Withdrawn, currently amended) A method of treating a patient having tumours a CD30-positive tumor, an inflammatory disease, an inflammatory-allergic disease, and/or an

autoimmune diseases disease, comprising dispensing a reagent according to claim 1 the reagent of claim 7.

22. (Withdrawn, currently amended) The method according to of Claim 21, characterized in that wherein the ~~tumour~~ tumor is a lymphoma or embryonal carcinoma.

23. (Canceled)

24. (Withdrawn, currently amended) The method according to ~~Claim 23~~ of claim 22, characterized in that ~~the CD30-positive~~ wherein the lymphoma is selected from the group consisting of a Hodgkin's lymphoma, an anaplastic large-cell lymphoma, ~~or~~ an acute form of adult T-cell leukemia, and a ~~or~~ lymphomatous form of adult T-cell ~~leukaemia~~ leukemia.

25. (Withdrawn, currently amended) The method according to of claim 21, characterized in that wherein 10 to 1000 mg/m<sup>2</sup> body surface of the reagent is dispensed.

26. (Withdrawn, currently amended) The method according to of Claim 25, characterized in that wherein 20 to 400 mg/m<sup>2</sup> body surface of the reagent is dispensed.

27. (Withdrawn, currently amended) The method according to of claim 21, characterized in that wherein the reagent is dispensed ~~i.v.~~ intravenously.

28. (Withdrawn, currently amended) A method of making a composition for the suppression or avoidance of a rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells comprising incorporating a reagent according to claim 1 the reagent of claim 7 into a the composition.

29. (Currently amended) ~~Pharmaceutical~~ A composition containing a reagent according to claim 1 comprising the reagent of claim 7.

30. (Currently amended) ~~Kit for the diagnosis in~~ A kit for diagnosing CD30-positive neoplasies, and inflammatory diseases, ~~containing a reagent according to claim 1 together with comprising the reagent of claim 7 and~~ instructions for use for the reagent.

31. (New) The method of claim 19, wherein step (a) is carried out *in vitro*.
32. (New) The method of claim 19, wherein step (a) is carried out *in vivo*.
33. (New) The method of claim 32, wherein step (b) comprises scintigraphy.